Next 10 |
2024-03-28 05:55:00 ET Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companie...
2024-03-22 12:40:30 ET Intellia Therapeutics ( NASDAQ: NTLA ) is opting out of an agreement with Regeneron Pharmaceuticals ( NASDAQ: REGN ) to co-develop a factor IX gene editing therapy for hemophilia A and B, the biotechnology firm disclosed in a filing on Friday.... ...
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of ...
2024-03-09 09:45:00 ET Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more clinical wins and several more launches in this field. Unfortunately, I...
2024-03-06 10:35:00 ET The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the stock, estimating that it'd climb by 119% to $73. But, per managem...
2024-02-29 05:50:00 ET You've no doubt seen mutual fund warnings that past performance isn't necessarily indicative of future results. This caution applies to stocks as well. However, it doesn't just mean that investments that have performed well in the past may not keep winning; it also im...
2024-02-21 11:33:57 ET More on Intellia Therapeutics Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier Biotech And Pharma Diversification Pays Off CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr, Intellia, and Recur...
2024-02-20 05:02:00 ET Cathie Wood's success is based on two main things: finding innovators and betting on them for the long term. The founder and chief executive officer of Ark Invest goes for innovators in all areas, from information technology to healthcare, and this helped her flagship...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-02-17 01:59:00 ET Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of the new bull market shaping up right now, it likely has a good s...
News, Short Squeeze, Breakout and More Instantly...
Intellia Therapeutics Inc. Company Name:
NTLA Stock Symbol:
NASDAQ Market:
Intellia Therapeutics Inc. Website:
2024-03-28 05:55:00 ET Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companie...
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of ...
2024-03-09 09:45:00 ET Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more clinical wins and several more launches in this field. Unfortunately, I...